RIKEN Center for Sustainable Resource Science, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan.
RIKEN Center for Biosystems Dynamic Research, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan.
Bioorg Med Chem. 2022 Jul 15;66:116830. doi: 10.1016/j.bmc.2022.116830. Epub 2022 May 14.
The identification, structure-activity relationships (SARs), and biological effects of new antimalarials consisting of a 2,3,4,9-tetrahydro-1H-β-carboline core, a coumarin ring, and an oxyalkanoyl linker are described. A cell-based phenotypic approach was employed in this search for novel antimalarial drugs with unique modes of action. Our screening campaign of the RIKEN compound library succeeded in the identification of the known tetrahydro-β-carboline derivative (4e) as a hit compound showing significant in vitro activity. SAR studies on this chemical series led to the discovery of compound 4h having a (R)-methyl group on the oxyacetyl linker with potent inhibition of parasite growth (IC = 2.0 nM). Compound 4h was also found to exhibit significant in vivo antimalarial effects in mouse models. Furthermore, molecular modeling studies on 4e, 4h, and its diastereomer (4j) suggested that the (R)-methyl group of 4h forces the preferential adoption of a specific conformer which is considered to be an active conformer.
描述了由 2,3,4,9-四氢-1H-β-咔啉核心、香豆素环和氧烷酰连接子组成的新型抗疟药物的鉴定、结构-活性关系 (SARs) 和生物学效应。在寻找具有独特作用模式的新型抗疟药物时,我们采用了基于细胞的表型方法。我们对 RIKEN 化合物库的筛选活动成功地确定了已知的四氢-β-咔啉衍生物 (4e) 作为具有显著体外活性的命中化合物。对该化学系列的 SAR 研究发现,具有氧乙酰连接子上 (R)-甲基的化合物 4h 对寄生虫生长具有很强的抑制作用 (IC = 2.0 nM)。化合物 4h 还在小鼠模型中表现出显著的体内抗疟作用。此外,对 4e、4h 及其非对映异构体 (4j) 的分子建模研究表明,4h 中的 (R)-甲基基团迫使它优先采用一种被认为是活性构象的特定构象。